The Perceval valve, which originally won CE Mark last year, was previously limited to patients aged 75 or older. The new indication lowers the age to 65 for patients with aortic valve stenosis or steno-insufficiency.
The newly approved next-generation surgical instruments aim to ease surgery and minimize surgical trauma and morbidity, according to a press release.
That’s more good news for the European healthcare giant, which earlier this year announced a $14 million buyout of cannula-maker California Medical Technologies.
The cardiac device titan is also looking to boost its footprint in the U.S., where it’s a back-bencher compared with more established competitors like Medtronic (NYSE:MDT), Boston Scientific (NYSE:BSX) and St. Jude Medical (NYSE:STJ).
SRN shares gained 0.4% today, closting at $1.76.
On June 4-5, DeviceTalks is taking over the Twin Cities medtech industry with one of the most anticipated conferences of the spring, bringing you the best and brightest minds in the industry.
Heidi Dohse: Sr. Program Manager, Healthcare, Google, Founder, Tour de Heart Foundation, Acessa Health Inc. Michael J. Pederson: Senior Vice President, Cardiac Arrhythmias and Heart Failure Division, Abbott Hon. Melvin Carter: Mayor, Saint Paul Tim Philips: Compliance Officer, FDA’s Office of Medical Device and Radiological Health Operations Dr. Myriam J. Curet, MD, FACS: Chief Medical Officer, Intuitive Surgical
Take a look at our incredible line up of speakers and join us now.
Use the code "KEYNOTE" to save 15% on the cost of registration.